Abstract: The present invention relates to a method for evaluating the state of cell differentiation during the process of inducing differentiation of human induced pluripotent stem cells (iPS cells) into retinal pigment epithelial cells. The present invention further relates to a method for evaluating the state of cell differentiation during the process of inducing differentiation of human embryonic stem cells (ES cells) into retinal pigment epithelial cells.

Abstract: The invention provides a method for predicting a differentiation potential of a pluripotent stem cell comprising measuring an expression level of CHD7 of the human pluripotent stem cell. The invention also provides a method for evaluating a medium for a human pluripotent stem cell comprising measuring an expression level of CHD7 of the pluripotent stem cell.

Abstract: The invention provides a method of removing or reducing undifferentiated cells from a differentiated cell population contaminated or having a risk of contamination with undifferentiated cells by contacting a pigment epithelium-derived factor with the differentiated cell population to induce apoptosis of the undifferentiated cells. The invention also provides an agent for cell transplantation therapy, containing a differentiated cell population substantially free of an undifferentiated cell, which is obtained by the method, as well as an agent for inducing apoptosis of an undifferentiated cell, containing a pigment epithelium-derived factor, and combined use of the aforementioned agent for cell transplantation therapy and the aforementioned agent for inducing apoptosis.

Abstract: The invention provides a method of removing or reducing undifferentiated cells from a differentiated cell population contaminated or having a risk of contamination with undifferentiated cells by contacting a pigment epithelium-derived factor with the differentiated cell population to induce apoptosis of the undifferentiated cells. The invention also provides an agent for cell transplantation therapy, containing a differentiated cell population substantially free of an undifferentiated cell, which is obtained by the method, as well as an agent for inducing apoptosis of an undifferentiated cell, containing a pigment epithelium-derived factor, and combined use of the aforementioned agent for cell transplantation therapy and the aforementioned agent for inducing apoptosis.

Abstract: The present invention provides a method of simply and uniformly subculturing pluripotent stem cells. The method includes the steps of dispersing cell masses obtained from passaging of the pluripotent stem cells into a single cell level, and subsequently, rapidly forming cell aggregates.

Abstract: The present invention provides a method of treatment for ischemic heart disease administering a scar formation accelerator containing at least one selected from SFRP2, SFRP4, Midkine, Pleiotrophin and Thymosin beta-10 as an effective ingredient to promote scar formation less fibrosis and retaining elasticity, and thereby improving cardiac function.

Abstract: The present invention provides a method of treatment for ischemic heart disease administering a scar formation accelerator containing at least one selected from SFRP2, SFRP4, Midkine, Pleiotrophin and Thymosin beta-10 as an effective ingredient to promote scar formation less fibrosis and retaining elasticity, and thereby improving cardiac function.

Abstract: A method for injecting a liquid drug containing a biological material is provided, which comprises the step of injecting the liquid drug containing the biological material contained in an injector into a subject at a predetermined range of velocity.

Abstract: A method for injecting a liquid drug containing a biological material is provided, which comprises the step of injecting the liquid drug containing the biological material contained in an injector into a subject at a predetermined range of velocity.